HDL Therapeutics, Inc. signed a non-binding letter of intent to acquire Swiftmerge Acquisition Corp. (NasdaqGM:IVCP) in a reverse merger transaction on April 24, 2023. Completion of a business combination with HDL Therapeutics is subject to, among other matters, the completion of due diligence, the negotiation of a definitive agreement providing for the transaction, satisfaction of the conditions negotiated therein and approval of the transaction by the board and shareholders of both Swiftmerge and HDL Therapeutics.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.84 USD | -0.09% | +0.37% | -0.28% |
1st Jan change | Capi. | |
---|---|---|
-0.28% | 74.14M | |
+190.94% | 6.96B | |
+2.14% | 982M | |
+41.91% | 872M | |
+26.98% | 830M | |
+1.72% | 664M | |
+5.92% | 642M | |
-.--% | 600M | |
+3.61% | 503M | |
-.--% | 500M |
- Stock Market
- Equities
- IVCP Stock
- News Swiftmerge Acquisition Corp.
- HDL Therapeutics, Inc. signed a non-binding letter of intent to acquire Swiftmerge Acquisition Corp. in a reverse merger transaction.